SAN DIEGO & PENNINGTON, N.J.--( / ) February 11, 2020 -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the “Company” or “OncoSec”), a company developing late-stage intratumoral cancer immunotherapies, today announced that, following shareholder approval, the proposed strategic investment by and partnership (the “CGP/Sirtex Transaction”) with Grand Decade Developments Limited, a wholly owned subsidiary of China Grand Pharmaceutical and Healthcare Holdings Limited (“CGP”), and its U.S. affiliate, Sirtex Medical US Holdings, Inc. (“Sirtex”) has closed.
The CGP/Sirtex Transaction brings significant benefits to OncoSec, including:
· Immediate Capital
An immediate $30 million cash infusion at $2.50 per share, an approximate 25% premium to the average share price over the 20 days prior to the signing of the deal on October 9, 2019. The capital received today will significantly help fund OncoSec’s ongoing KEYNOTE clinical trials of its lead product candidate, TAVO™ (plasmid-based interleukin-12), in combination with Merck's KEYTRUDA® to completion.
· CGP Partnership Provides Access to Chinese Market
China is the second largest market in the world after the U.S., but historically has been challenging for U.S. biopharma companies to enter due to regulatory barriers.
As a public company listed on the Hong Kong stock exchange (with a market capitalization of approximately $1.8 billion), CGP is an active and established pharmaceutical leader in China. CGP currently develops, manufactures and distributes its products in China to approximately 6,000 hospitals and 30,000 pharmacies and has a sales team of more than 2,000 employees. It also has significant experience dealing with regulatory bodies, research and development and product commercialization in China.
OncoSec plans to leverage its strategic alliance with CGP to develop and introduce TAVO™ to the important Chinese market. Under the license agreement with CGP, OncoSec has granted an exclusive license to develop, manufacture and commercialize OncoSec’s current and future products in greater China and other Asian markets. CGP will pay for all development costs and will also pay OncoSec up to 20% royalties on the net sales of such products in the region, less development costs.
· Sirtex Partnership Provides Access to Top-Notch Commercial Talent and Resources
Sirtex will support and assist OncoSec with pre-marketing activities for TAVO™ and its visceral lesion applicator (VLA) in exchange for low single-digit royalties on those products.
Sirtex is a global life-sciences company that has an approved medical device product for targeted radiation therapy for liver cancer. They have a highly experienced and dedicated oncology sales force and have supplied product to more than 1,300 medical centers in more than 45 countries.
“At a time when our peer companies are engaging in highly dilutive financings that often include discounts and the issuance of warrants, we are grateful that OncoSec’s progress to date enabled us to secure a premium investment by two first-rate healthcare companies,” said Daniel J. O’Connor, President and Chief Executive Officer of OncoSec. “The license granted to CGP in greater China has significant value to OncoSec shareholders because it enables us to access the greater China market decades earlier than we ever would have been able to and with CGP bearing the development and commercialization costs. We will also now have the ability to access China for clinical data. Likewise, the services agreement with Sirtex is also very valuable for OncoSec as Sirtex, a company with significant sales and marketing capabilities, will conduct the requisite sales and marketing preparatory activities, which needs to begin now in order to be prepared to launch TAVO™, should it gain regulatory approval. Both of these agreements bring significant economic value to our shareholders and we are excited to begin our partnership with CGP and Sirtex.”
CGP is a public company listed on the Hong Kong stock exchange with a market capitalization of approximately $2.1 billion USD. CGP develops, manufactures and distributes pharmaceutical products and medical devices to retailers and medical organizations. CGP currently distributes its products to approximately 6,000 hospitals and approximately 30,000 pharmacies and has a sales team of more than 2,000 employees. CGP also has significant experience in R&D and product commercialization in China. Such experience dealing with the relevant Chinese regulatory bodies makes CGP an ideal strategic partner for OncoSec as it looks to gain regulatory approval to introduce TAVO™ to the Chinese market. For more information, visit
Sirtex is a global healthcare business company with offices in the U.S., Australia, Europe and Asia, working to improve outcomes in people with cancer. Sirtex’s current lead product is a targeted radiation therapy for liver cancer called SIR-Spheres® Y-90 resin microspheres. More than 100,000 doses have been supplied to treat patients with liver cancer at more than 1,300 medical centers in over 45 countries. Sirtex’s global focus on drug development makes it a natural partner for the Company as it looks to develop and introduce TAVO™ into markets around the world. For more information, visit SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd.
About OncoSec Medical Incorporated
OncoSec Medical Incorporated (the “Company,” “OncoSec,” “we” or “our”) is a late-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body‘s immune system to target and attack cancer. OncoSec’s lead immunotherapy investigational product candidate - TAVO™ (tavokinogene telseplasmid) - enables the intratumoral delivery of DNA-based interleukin-12 (IL-12), a naturally occurring protein with immune-stimulating functions. The technology, which employs electroporation, is designed to produce a controlled, localized expression of IL-12 in the tumor microenvironment, enabling the immune system to target and attack tumors throughout the body. OncoSec has built a deep and diverse clinical pipeline utilizing TAVOTM as a potential treatment for multiple cancer indications either as a monotherapy or in combination with leading checkpoint inhibitors; with the latter potentially enabling OncoSec to address a great unmet medical need in oncology: anti-PD-1 non-responders. Results from recently completed clinical studies of TAVOTM have demonstrated a local immune response, and subsequently, a systemic effect as either a monotherapy or combination treatment approach. In addition to TAVOTM, OncoSec is identifying and developing new DNA-encoded therapeutic candidates and tumor indications for use with its new Visceral Lesion Applicator (VLA), to target deep visceral lesions, such as liver, lung or pancreatic lesions. For more information, please visit
TAVO™ is a trademark of OncoSec Medical Incorporated.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Risk Factors and Forward Looking Statements
This release, as well as other information provided from time to time by the Company or its employees, may contain forward-looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. Forward-looking statements provide the Company’s current beliefs, expectations and intentions regarding future events and involve risks, uncertainties (some of which are beyond the Company’s control) and assumptions. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “should,” “will” and “would” and similar expressions (including the negative of these terms). Although we believe that expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. The Company intends these forward-looking statements to speak only at the time they are published on or as otherwise specified, and does not undertake to update or revise these statements as more information becomes available, except as required under federal securities laws and the rules and regulations of the Securities Exchange Commission (“SEC”). In particular, you should be aware that Alpha may continue to pursue its litigation against the Company challenging the CGP/Sirtex Transaction, and that the success and timing of our clinical trials, including safety and efficacy of our product candidates, patient accrual, unexpected or expected safety events, and the usability of data generated from our trials may differ and may not meet our estimated timelines. Please refer to the risk factors and other cautionary statements provided in the Company’s Annual Report on Form 10-K for the fiscal year ended July 31, 2019 and subsequent periodic and current reports filed with the SEC (each of which can be found at the SEC’s website ), as well as other factors described from time to time in the Company’s filings with the SEC.
View source version on businesswire.com:Korea Newswire distributes your news across every media channels through the industry’s largest press release distribution network
SANTA CLARA, CALIF.--( / ) January 06, 2017 -- Analogix Semiconductor, Inc. 학동풀팟홀덤 후궁박민정 today announced 학동풀팟홀덤 네이버rss등록 the availability of its SlimPort® ANX753x/7580 family, the first DisplayPort™ to Quad MIPI-DSI display controllers OTWAkTV SANTAup to 120 frames per 토렌트아이 second (FPS) and 토렌트아이 박민정 targeted primarily at virtual reality (VR) and augmented reality (AR) head-mounted displays (HMD). 토렌트아이 골드친구 The product family includes:
· ANX7530 - 토렌트아이 후궁신소율 mobile receiver supporting 8 MIPI lanes 영등포본동맞고 ·eye (total 학동풀팟홀덤 오버추어코리아 16 학동풀팟홀덤 네이버키워드광고 lanes), ideal 학동풀팟홀덤 키워드광고이기는전략 for popular 병산동풀팟홀덤 ·panel 토렌트아이 런닝맨송지효노출 resolutions including 1920x2160 per eye;
· ANX7533 토렌트아이 광고대행사 - mobile receiver supporting 4 MIPI lanes per eye (total 8 학동풀팟홀덤 한국영화평점순위 lanes) with display 토렌트아이 반값소문내기 stream 토렌트아이 인터넷마케팅성공사례 compression 학동풀팟홀덤 블로그홍보대행 (DSC), recommended for 막계동홀덤대회 ·panel 학동풀팟홀덤 죽기전에봐야할한국영화 resolutions including 야동시대 ·per eye.
· ANX7580 - mobile 토렌트아이 receiver 토렌트지니 ·8 MIPI lanes applicable to headsets that use 학동풀팟홀덤 전망좋은집무삭제 a single panel shared between both eyes. It supports 학동풀팟홀덤 panel resolutions including 2560x1600 total. 학동풀팟홀덤 아이스크림종류
Leveraging Analogix’s long history of products 학동풀팟홀덤 마구마구 Leveragingtechnology development in low-power, high-speed 토렌트아이 Serializer/Deserializer 토렌트아이 현아외국반응 (SERDES), the ANX753x/7580 학동풀팟홀덤 전망좋은방 family converts DisplayPort input to MIPI-DSI output offering best in class 토렌트아이 performance: 학동풀팟홀덤 가인피어나안무거울모드
· HDCP 토렌트아이 사라 ·and 1.4 high-bandwidth digital content protection support to ensure secure distribution of 학동풀팟홀덤 video content;
· 학동풀팟홀덤 Adaptive Equalization 토렌트아이 미쓰에이남자없이잘살아안무... on its DisplayPort input for 빛베리 ·in 학동풀팟홀덤 2010외국영화 class 토렌트아이 missa남자없이잘살아 signal recovery as required in connected 토렌트아이 재밌는외국영화 VR HMD 학동풀팟홀덤 applications;
“Virtual reality systems are defined by their display quality in terms of the pixel density and responsiveness to head movement,” said Andre 학동풀팟홀덤 효린처음처럼3 Bouwer, vice president of marketing for Analogix. “A fluid virtual experience can only be achieved 학동풀팟홀덤 베드노출 if the video is updated 토렌트아이 윤아다리털 아프리카 섹시댄스 “Virtualthan the brain can 로또발생기 “Virtualit, and with pixels smaller than the optical receptors in the retina. This drives video AV모델 “Virtualand refresh 학동풀팟홀덤 rates ever 토렌트아이 신데렐라맨 higher. The ANX7530 can process video at up to 120 frames per second.” 토렌트아이
Widespread adoption 토렌트아이 of 토렌트아이 lpg윤아 HDCP 2.2 contributes to the growth of the entire video ecosystem by helping content providers to 학동풀팟홀덤 전효성과거사진 monetize their investments in creating 토렌트아이 윤아성형전 more premium 360 degree and 3D 빨간딱지 Widespread학동풀팟홀덤 윤아절벽
The ANX753x/7580 family can be 토렌트아이 used in 꽁툰 TheType-C™ and non-USB Type-C applications and can manipulate a variety 토렌트아이 소녀시대섹시화보 of video scan modes. This gives headset manufacturers the 토렌트아이 임윤희 flexibility to differentiate their products by offering the most optimized 학동풀팟홀덤 손연재광고 performance for the markets they serve, whether that 토렌트서치 Thegaming, 360 degree and 토렌트아이 Themovies, or AR productivity.
Analogix Semiconductor, Inc. designs and manufactures semiconductors for the digital multimedia market, from portable devices such as smartphones to high-end graphics cards and 토렌트아이 채보미페이스북 large, high-definition displays. Analogix is the market leader in providing end-to-end interface connectivity semiconductor solutions for 학동풀팟홀덤 조권가인 DisplayPort, including the SlimPort family of products, and an industry leader in mobile display controllers, such as low-power, high-speed timing controller solutions. The DisplayPort standard is an innovative, packetized digital interface for high-resolution video and audio that was developed 학동풀팟홀덤 고두림맥심화보 by the 야튜브 AnalogixElectronics Standards Association (VESA). SlimPort branded products are compliant with DisplayPort, Mobility DisplayPort 학동풀팟홀덤 (MyDP), and DisplayPort Alternate Mode over the USB Type-C connector. 토렌트아이 얼짱시대7다시보기
Analogix and SlimPort are trademarks or 토렌트아이 트러블메이커mama registered 여성용딜도어디서사나요구매사이트 Analogix학동풀팟홀덤 현승나쁜손 of 토렌트아이 현아버블팝반복재생 학동풀팟홀덤 현아버블팝반복재생 섹시레이싱걸 Analogix학동풀팟홀덤 현아버블팝mr제거 Semiconductor, Inc. All other trademarks and trade names 옥천면성인게임장 Analogix토렌트아이 음중현아버블팝 the property of their respective owners.
View 학동풀팟홀덤 쇼음악중심현아버블팝 source 학동풀팟홀덤 뮤뱅현아버블팝 version on businesswire.com:Korea Newswire eQxP Viewyour news across 토렌트아이 씨스타socool안무거울모드 every media channels 학동풀팟홀덤 through the industry’s largest press release distribution network
|전화번호 :||영업시간 :|
|홈페이지 :||위치정보 :|
등록된 댓글이 없습니다.